| Cat. No. |
Product Name |
Information |
| PC-43808 |
I-BET726
BET inhibitor
|
I-BET726 (GSK1324726A) is a potent and selective inhibitor of BET bromodomain with IC50 of 41 nM/31 nM/22 nM for BRD2/BRD3/BRD4 respectively. |
| PC-42230 |
TPOP146
CBP/p300 inhibitor
|
TPOP146 is a potent and selective CBP/p300 bromodomain inhibitor with Kd of 134 nM for CBP bromodomain, displays excellent selectivity over other bromodomains (>30-fold over BRD4 (1)). |
| PC-42029 |
Mivebresib
BET inhibitor
|
Mivebresib (ABBV-075) is a potent and orally available BET bromodomain inhibitor with Ki of 1.0, 12.2, 1.5, and 2.2 nM for BRD2, BRD3, BRD4 and BRDT, respectively. |
| PC-25104 |
Zavabresib
BET inhibitor
|
Zavabresib is a potent BET inhibitor with anticancer activity, inhibits prostate cancer cell growth with IC50 of 0.043 and 0.034 μM against LNCaP and 22Rv1 cells, respectively. |
| PC-24390 |
Y08197
CBP/EP300 inhibitor
|
Y08197 is a selective inhibitor of CBP/EP300 bromodomain, inhibits the CBP bromodomain with IC50 of 100.67 nM, high selectivity for CBP/EP300 over other bromodomain-containing proteins. |
| PC-24374 |
ZL0516
BRD4 BD1 inhibitor
|
ZL0516 is a potent, selective BRD4 BD1 inhibitor with IC50 of 84 nM, shows good selectivity over other BRD family proteins including BRD4 BD2. |
| PC-24237 |
KB-0118
BET bromodomain
|
KB-0118 is a selective BET bromodomain inhibitor with Kd of 36.7 uM for BRD2 BD1 and 47.4 uM for BRD4 BD1, shows immunomodulatory effects in inflammatory bowel disease (IBD). |
| PC-23888 |
LC-CE-7
CECR2 inhibitor
|
LC-CE-7 is a potent, sepecific and allosteric covalent CECR2 inhibitor with IC50 of 462 nM and Ki of 32.5 nM, exhibits covalent binding to Cys494 and allosteric regulation of the Kac pocket. |
| PC-23763 |
IEM930
GAS41/YEATS4 inhibitor
|
IEM930 is a small molecule inhibitor targeting the GAS41 YEATS domain (YEATS4)) with ITC binding Kd of 32.6 uM, inhibits GAS41/ITGA4-mediated PI3K/Akt/mTOR signaling pathway in glioma cells. |
| PC-23754 |
CZL-046
p300 bromodomain inhibitor
|
CZL-046 is a potent, selective, and orally active p300 bromodomain inhibitor with IC50 of 3.3 nM, exhibits antiproliferative activity in the multiple myeloma (MM) cell line (OPM-2, IC50=51.5 nM). |
| PC-22992 |
Y06014
BET inhibitor
|
Y06014 is a selective BRD4(1) inhibitor with IC50 of 4.87 uM. |
| PC-22925 |
GSK2801
BAZ2A/B inhibitor
|
GSK2801 is a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains with KD values of 136 and 257 nM for BAZ2B and BAZ2A, respectively. |
